Search Results
Your search for The matches 33902 pages
Showing 351 - 400New Studies Explore Relationships Between Heart Failure and Lymphoma, Arterial Thromboembolism and Cancer
In two studies recently reported in JACC: CardioOncology, Upshaw and colleagues1 examined the impact of preexisting heart failure on mortality in older patients in the United States with newly diagnosed Hodgkin lymphoma, and Gon and colleagues2 analyzed the incidence and impact of arterial...
IDEA Awardees’ Reflections on the 2024 ASCO Annual Meeting
It happened! We received the International Development and Education Award (IDEA) from Conquer Cancer®, the ASCO Foundation, and it was a journey of growth, global collaboration, leadership, mentorship, and more. We have much to share after this breakthrough in our careers. The ASCO Annual Meeting...
Phase III ALEXANDRA/IMpassion030: No Survival Benefit for Adjuvant Atezolizumab in Triple-Negative Breast Cancer
In patients with early-stage triple-negative breast cancer, the addition of atezolizumab to standard adjuvant chemotherapy provided no benefit over chemotherapy alone in the final analysis of the phase III ALEXANDRA/IMpassion030 trial. The results were presented at the 2024 European Breast Cancer...
Addition of Oxaliplatin to Fluoropyrimidine/Bevacizumab in Initial Therapy for Metastatic Colorectal Cancer in Older Patients
In a Japanese phase III trial (JCOG1018) reported in the Journal of Clinical Oncology, Takashima et al found that adding oxaliplatin to fluoropyrimidine/bevacizumab did not improve progression-free survival in the initial treatment of older patients with unresectable metastatic colorectal cancer....
Sacituzumab Govitecan in Cisplatin-Ineligible Advanced Urothelial Cancer After ICI Therapy
In cohort 2 of the phase II TROPHY-U-01 study, reported in the Journal of Clinical Oncology, Petrylak et al found that sacituzumab govitecan-hziy was active in cisplatin-ineligible patients with locally advanced or metastatic urothelial cancer progressing after immune checkpoint inhibitor (ICI)...
Liquid Biopsy May Predict Risk of Venous Thromboembolism in Patients With Cancer
Researchers have found that a liquid biopsy may help to predict whether patients with cancer may be at risk of developing venous thromboembolism, according to a recent study published by Jee et al in Nature Medicine. Background Liquid biopsy tests—such as MSK-ACCESS—increasingly play a role in...
Can AI Tool Improve Detection of Immune-Related Adverse Events in Patients With Cancer?
Researchers have explored whether an artificial intelligence (AI)-based tool could help to detect immune-related adverse events in patients with cancer, according to a recent study published by Sun et al in the Journal of Clinical Oncology. Background Although immune checkpoint inhibitors can...
Immune Checkpoint Inhibitor–Related Cardiotoxicity in Patients With Cancer
In a meta-analysis reported in JAMA Oncology, Nielsen et al estimated the risk of cardiotoxicity associated with immune checkpoint inhibitor (ICI) treatment of cancers. Study Details The meta-analysis included 83,315 unique patients in 589 unique trials of ICIs and ICI combination therapies. The...
Fam-Trastuzumab Deruxtecan-nxki in Unresectable or Metastatic HER2-Positive Solid Tumors
On April 5, 2024, fam-trastuzumab deruxtecan-nxki (T-DXd) was granted accelerated approval for adults with unresectable or metastatic HER2-positive (immunohistochemistry 3+) solid tumors who received prior systemic treatment and have no satisfactory alternative treatment options.1 Supporting...
Nivolumab in Combination With Cisplatin Plus Gemcitabine in Treatment of Unresectable or Metastatic Urothelial Carcinoma
Nivolumab (Opdivo) was approved for use in combination with cisplatin and gemcitabine for first-line treatment of patients with unresectable or metastatic urothelial carcinoma.1 Supporting Efficacy Data Approval was based on the open-label CheckMate 901 trial (ClinicalTrials.gov identifier...
New Collaborative Guideline Highlights the Importance of Multidisciplinary Care for Patients With Osteoradionecrosis
A joint guideline from the International Society of Oral Oncology–Multinational Association for Supportive Care in Cancer and ASCO seeks to fill a gap in the clinical guidance for patients with head and neck cancers who develop osteoradionecrosis following their head and neck radiation therapy.1...
Nivolumab Plus Chemotherapy Extends Survival in Lymph Node–Only Metastatic Urothelial Cancer
The combination of nivolumab plus gemcitabine/cisplatin chemotherapy achieved high response rates and durable responses and improved overall survival and progression-free survival compared with gemcitabine/cisplatin chemotherapy alone in patients with urothelial carcinoma and clinical evidence of...
Chinese Study Finds Radiation Alone May Be as Effective as Chemoradiation in Patients With Low-Risk Nasopharyngeal Cancer
Nasopharyngeal carcinoma is an aggressive malignant head and neck cancer that is highly prevalent in the southern and southwestern provinces of China. Although the incidence of the cancer is less than 1 per 100,000 in Europe, the United States, and the Pacific,1 data from the International Agency...
Mobile Phones May Not Be Linked to Brain Cancer, WHO-Backed Study Finds
Investigators have found that there may not be an association between mobile phone use and an increased risk of brain cancer, according to a recent World Health Organization (WHO)-commissioned review published by Karipidis et al in Environmental International. Background The WHO and other...
New Study Illuminates Variations in Performance Characteristics Between FIT Tests
Researchers have found substantial variations in the performance characteristics of five commonly used fecal immunochemical tests (FIT), according to a recent study published by Levy et al in the Annals of Internal Medicine. Background Stool-based tests like FIT are currently recommended for...
Belzutifan vs Everolimus in Previously Treated Advanced Renal Cell Carcinoma
As reported in The New England Journal of Medicine by Choueiri and colleagues, the phase III LITESPARK-005 trial has shown improved progression-free survival with the hypoxia-inducible factor–2α inhibitor belzutifan vs everolimus in previously treated patients with advanced clear-cell renal cell...
Delays in Oral Antimyeloma Treatment Initiation: Role of Social Determinants of Health
A retrospective cohort study published in Blood Cancer Journal by Gasoyan et al revealed discrepancies between the timing of the initiation of any treatment and the fill of prescriptions for oral antimyeloma medications in patients with multiple myeloma, with a lower likelihood of Black and older...
Use of Immune Checkpoint Inhibitors Under Study in High-Risk, Hormone Receptor–Positive, Early-Stage Breast Cancer
Clinical trials are now demonstrating the value of immune checkpoint inhibitors as neoadjuvant therapy in certain subsets of patients with hormone receptor–positive, HER2-negative breast cancer. Hope S. Rugo, MD, FASCO, described this newer approach—specifically, which subsets of patients may...
Prescription for Progress: Lancet Oncology Commission’s Practical Strategies for Global Cancer Surgery
In certain regions of the world, cancer claims more lives than HIV, tuberculosis, and malaria combined, yet surgery has been relegated to the sidelines of global health initiatives. This critical need to address global inequities in access to safe, timely, and affordable cancer surgery led to the...
Recurrent or Metastatic HNSCC: Overall Survival With Immunotherapy
In a study reported in JAMA Network Open, Sun et al analyzed survival outcomes with immune checkpoint inhibitor (ICI) treatment used in first- or second-line therapy, with treatment continuation vs discontinuation, and with treatment rechallenge in patients with recurrent or metastatic head and...
Effect of False-Positives on Adherence to Subsequent Breast Cancer Screening
Patients may be less likely to return for subsequent screening mammography following a false-positive recall for additional imaging or biopsy, according to a recent study published by Miglioretti et al in the Annals of Internal Medicine. The findings raised concerns regarding the potential...
Chronic Conditions Could Delay Lung Cancer Diagnoses
Investigators have revealed that patients with certain chronic conditions may face delays in being diagnosed with lung cancer, according to a recent study published by Rogers et al in the British Journal of Cancer. Background Lung cancer is currently one of the leading causes of cancer-related...
Menopausal Hormone Therapy and Risk of Ovarian and Endometrial Cancers
In a long-term follow-up of Women’s Health Initiative (WHI) randomized trials reported in the Journal of Clinical Oncology, Rowan T. Chlebowski, MD, PhD, and colleagues identified risks of ovarian and endometrial cancers associated with the use of menopausal hormone therapy. Study Details The...
T-DXd Effective for Breast Tumors With HER2-Low and HER2-Ultralow Expression in Earlier Line of Therapy
In patients with hormone receptor–positive metastatic breast cancers with HER2-low or HER2-ultralow expression, treatment with the antibody-drug conjugate fam-trastuzumab deruxtecan-nxki (T-DXd) was found to be superior to chemotherapy after one or more lines of endocrine therapy. In...
Adjuvant Pembrolizumab vs Placebo in Stage III Melanoma: Long-Term Health-Related Quality of Life
In an analysis from the phase III EORTC 1325-MG/KEYNOTE-054 trial reported in The Lancet Oncology, Bührer et al found that adjuvant pembrolizumab was not associated with significant differences in long-term health-related quality of life (HRQOL) compared with placebo in patients with stage III...
Oral Cannabis Extract for Refractory Chemotherapy-Induced Nausea and Vomiting
In an Australian phase II/III trial reported in the Journal of Clinical Oncology, Grimison et al found that oral cannabis extract improved the antiemetic complete response rate vs placebo in patients with cancer who had refractory chemotherapy-induced nausea and vomiting (CINV) despite use of...
Early-Onset Colorectal Cancer: Rurality and Poverty May Be Linked to Lower Survival
Patients with early-onset colorectal cancer living in rural vs urban areas were found to have a lower likelihood of 5-year survival, with persistent poverty compounding this association in some age groups, according to an analysis published in a research letter by Tsai et al in JAMA Network Open....
Structural Racism and Cancer Risk From Traffic-Related Air Pollution
Multiple aspects of structural racism may contribute to an increased exposure to carcinogenic traffic-related air pollution, according to a recent study published by White and Ekenga in Cancer. Background High levels of traffic-related air pollutants have been linked to an elevated risk of...
What Is the Better Target for Bispecific Antibodies in Multiple Myeloma: BCMA or GPRC5D?
For relapsed or refractory multiple myeloma, there are three available bispecific antibodies—two that target B-cell maturation antigen (BCMA) and one that targets G protein–coupled receptor class C group 5 member D (GPRC5D). Which is the preferred target? This question was addressed at the 2024...
Impact of Breast Cancer Screening Interval on Stage at Diagnosis and Overall Survival
Annual mammographic screening appeared to be associated with a reduced risk of late-stage breast cancer and an overall survival benefit across clinical and demographic subgroups of patients older than age 40, according to an observational analysis reported by Zuley et al in the Journal of Clinical...
Genomic Determinants of Relapse in Childhood ALL
In a study reported in the Journal of Clinical Oncology, Chang et al identified potential genomic determinants of relapse risk in pediatric acute lymphoblastic leukemia (ALL). As stated by the investigators, “Although cure rates for childhood ALL exceed 90%, ALL remains a leading cause of cancer...
Ruxolitinib for Corticosteroid-Refractory Sclerotic Chronic GVHD
In a phase II study reported in the Journal of Clinical Oncology, Vijaya Raj Bhatt, MS, MBBS, and colleagues found that ruxolitinib produced responses in patients with corticosteroid-refractory sclerotic chronic graft-vs-host disease (GVHD) after transplantation for hematologic malignancies. Study ...
HPV Vaccination Rate Among Young Female Patients With Psychiatric Diagnoses
The rate of human papillomavirus (HPV) vaccination may be lower among female individuals with mental health issues or neurodevelopmental conditions compared with their peers, according to a recent study published by Hu et al in The Lancet Public Health. Background The HPV vaccine is capable of...
Preclinical Study Examines Novel Pancreatic Cancer Treatment
Early-stage research demonstrated the synergistic effects of a novel nanoparticle drug–delivery system to activate an immune pathway in combination with tumor-targeting agents in mice with pancreatic ductal adenocarcinoma, according to a preclinical study published by Chibaya et al in Science...
FDA Approves Cancer Biomarker Test, Companion Diagnostic Indications
The U.S. Food and Drug Administration (FDA) has approved the in vitro diagnostic TruSight Oncology (TSO) Comprehensive test and its first two companion diagnostic indications. This targeted sequencing panel interrogates over 500 genes to profile a patient's solid tumor, helping to increase the...
ICI-Based Strategies in Advanced, Progressing EGFR-Mutated NSCLC
As reported in The Lancet Oncology by Zhao et al, meta-analyses of trials of immune checkpoint inhibitors (ICIs) in patients with advanced EGFR-mutated non–small cell lung cancer (NSCLC) progressing on EGFR tyrosine kinase inhibitor (TKI) treatment indicate that the optimal treatment strategy is...
Previously Untreated Cancer of Unknown Primary: Site-Specific Therapy Guided by a 90-Gene Expression Assay
In a Chinese single-center trial (Fudan CUP-001) reported in The Lancet Oncology, Liu et al found that site-specific therapy guided by a 90-gene expression assay improved progression-free survival vs empirical chemotherapy in previously untreated patients with cancer of unknown primary (CUP) who...
Can a Blood Test Predict Obesity-Related Cancer Risk in Patients With Type 2 Diabetes?
Researchers have found that a blood test may effectively identify patients with type 2 diabetes who may be at a higher risk of developing certain cancers, according to new findings to be presented by Bennetsen et al at the upcoming European Association for the Study of Diabetes Annual Meeting 2024...
Many Women Unaware of Preventive Benefits of Diet for Breast Cancer Risk
Just 28% of U.S. women may be aware that a healthful diet can lower the risk of developing breast cancer, according to a recent survey conducted by the Physicians Committee for Responsible Medicine and Morning Consult. Background The Physicians Committee for Responsible Medicine is a national...
Adjuvant Everolimus in Localized Papillary and Chromophobe Non–Clear Cell Renal Cell Carcinoma
In a subgroup analysis of the EVEREST trial reported in JAMA Network Open, Gulati et al found that adjuvant everolimus did not improve recurrence-free survival vs placebo in patients with localized papillary or chromophobe non–clear cell renal cell carcinoma (RCC). Study Details In the trial,...
Medication-Related Osteonecrosis of the Jaw in Patients With Breast Cancer
In an Austrian study reported in the Journal of Clinical Oncology, Brunner et al identified the incidence of medication-related osteonecrosis of the jaw over 20 years of follow-up in patients with breast cancer who had bone metastases and were receiving antiresorptive medication. Study Details and...
Remembering a Pioneer in Melanoma and Immunotherapy: Jeffrey S. Weber, MD, PhD, FASCO
Jeffrey S. Weber, MD, PhD, FASCO, an internationally recognized pioneer in melanoma and cancer immunotherapy, died on August 19, 2024, according to an announcement from the Melanoma Research Foundation. He most recently served as Deputy Director of the Laura and Isaac Perlmutter Cancer Center at...
Cancer Has Robbed Me of My Fertility and My Olympic Dreams
I was a track and field athlete throughout college, and my goal was to try out for the Olympics, but cancer had other plans for me. In 2010, while in my senior year in college, I began having sharp, shooting pains in my shoulders, which I initially attributed to overzealous training. But the pain...
Olaparib May Be Effective Without Hormone Therapy in Some Men With Biochemically Recurrent Prostate Cancer
Olaparib may be effective in treating men with biochemically recurrent prostate cancer without accompanying hormone therapy, according to a novel study published by Marshall et al in JAMA Oncology. Background Although most men with localized prostate cancer can be cured with surgery or primary...
Pregnancy-Associated Cancer Incidence and Risks of Adverse Obstetric, Perinatal Outcomes
Women with breast cancer during pregnancy may have a good prognosis and a low risk of adverse obstetric and perinatal outcomes, according to three recent studies published by Lundberg et al in Acta Obstetricia et Gynecologica Scandinavica, Gkekos et al in ESMO Open, and Lundberg et al in Acta...
Ponatinib With Chemotherapy for Newly Diagnosed Philadelphia Chromosome–Positive ALL
On March 19, 2024, ponatinib (Iclusig) was granted accelerated approval for use with chemotherapy in adults with newly diagnosed Philadelphia chromosome–positive acute lymphoblastic leukemia (ALL).1 Ponatinib is a multitargeted kinase inhibitor. Supporting Efficacy Data and How It Is Used Approval ...
Inotuzumab Ozogamicin for Pediatric Acute Lymphoblastic Leukemia
On March 6, 2024, the anti-CD22 monoclonal antibody inotuzumab ozogamicin (Besponsa), which is bound to a toxic natural calicheamicin, was approved for pediatric patients aged 1 year or older with relapsed or refractory CD22-positive B-cell precursor acute lymphoblastic leukemia.1 Supporting...
CAR T-Cell Therapy in Refractory Follicular Lymphoma
On May 15, 2024, lisocabtagene maraleucel (Breyanzi) was granted accelerated approval for adults with relapsed or refractory follicular lymphoma with two or more prior lines of systemic therapy.1 The agent is a CD19-directed genetically modified autologous T-cell immunotherapy. Supporting Efficacy...
Hypofractionated vs Conventionally Fractionated Radiation After Implant-Based Breast Reconstruction
In a trial reported in JAMA Oncology, Julia S. Wong, MD, and colleagues found that hypofractionated postmastectomy radiation therapy did not improve outcomes in the physical well-being domain of the Functional Assessment of Cancer Therapy–Breast (FACT-B) assessment vs conventionally fractionated...
Disparities in Exposure to Tobacco Content on Streaming Platforms
The risk of encountering tobacco products being advertised, marketed, or promoted on streaming services based on race, ethnicity, socioeconomic status, and smoking habits was identified in a recent study published by Onyeaka et al in JAMA Network Open. Background The World Health Organization...
